3 European Life Science Tools Stocks Investors May Want To Watch Now
Europe’s big drug makers are warning that the region is slipping in the global race for R&D and clinical trials, and that shift could quietly reshape where capital flows next. If governments respond with friendlier rules and funding, the real beneficiaries may be the lab tool suppliers and clinical service providers working behind the scenes. This article walks through 3 stocks from our European life-science tools screener that appear closely tied to this turning point.
The three stocks highlighted next are only a starter set from this theme, and the full screen surfaced 16 more European life-science tools and clinical research enablers with equally rich stories that are not covered below. To see the wider field and start to identify your own highest conviction plays, head straight to the European Life-Science Tools and Clinical Research Enablers screener.
Tecan Group (SWX:TECN)
Tecan Group plugs directly into the screener’s theme, supplying lab automation, reagents and diagnostics tools that drug developers depend on as Europe debates how much R&D and clinical trial activity to keep on home soil.
Tecan Group generates about CHF 378 million from its Life Sciences Business and roughly CHF 501 million from its Partnering Business, reflecting a mix of own-brand lab instruments and contract design and manufacturing, and the stock carries a market value of around CHF 2.6b.
"The expansion of recurring revenues through services and consumables (making up 62% of Life Sciences sales and growing) improves customer stickiness and visibility, which could lift net margins and lower volatility across cycles."
What happens if one unresolved pressure on Tecan’s lab-instrument demand shifts just as those higher quality recurring sales keep building?
If that pressure point is on your radar, read the full narrative for Tecan Group to see how Tecan Group’s recurring engine could decouple from headline instrument demand.
Gubra (CPSE:GUBRA)
Gubra plugs directly into the European Life-Science Tools and Clinical Research Enablers theme, running a peptide-focused preclinical CRO that supports drug developers at the earliest stages where shifting R&D budgets and obesity research priorities can quickly change demand for its lab services.
"Growing medical focus on obesity as a chronic disease and the need for differentiated treatments supports Gubra's obesity peptide pipeline, which can influence future milestone income and longer term revenue potential from partnered and wholly owned assets."
The real swing factor is how one emerging pressure on obesity and metabolic research funding shapes future demand for Gubra’s preclinical platforms.
Gubra is a Danish techbio group built around peptide drug discovery and preclinical contract research. CRO activities contribute about DKK 203 million and Biotech adds roughly DKK 88 million of revenue, and the stock is valued at around DKK 5.1b.
That funding squeeze is the real hinge point, and the full narrative for Gubra shows how Gubra’s model could still turn that pressure into accelerating leverage on its obesity pipeline.
Eurofins Scientific (ENXTPA:ERF)
Eurofins Scientific is one of the clearest ways to play the European Life-Science Tools and Clinical Research Enablers theme, with a testing network that touches everything from pharma R&D and clinical diagnostics to regulatory checks that drug developers rely on.
Eurofins Scientific runs a global network of laboratories focused on analytical testing, earning about €7.4b from its Analytical Testing division, and the stock is valued at roughly €13.6b.
"Investments in automation, digitalization, and its hub-and-spoke laboratory infrastructure are expected to materially improve operating efficiency and scalability by 2027. Heightened regulatory standards and demographic trends are supporting stable, resilient demand across core testing and diagnostics services."
The key unknown is how one unresolved funding and regulation shift in European pharma will ultimately affect Eurofins Scientific’s pricing power and volume mix.
That hinge on funding and regulation is exactly what the full narrative for Eurofins Scientific unpacks, highlighting where Eurofins Scientific might still find potential opportunity as the cycle resets.
Seeking Alternatives Before The Crowd
Fresh ideas move first. Breakout trends, shifting momentum and under-the-radar stories can get caught quickly once attention flies in. Scan these curated shortlists while it matters and act now.
- Spot cash-rich operators before momentum headlines arrive by running through the list of solid balance sheet and fundamentals (197 results), curated to surface businesses that pair sturdy finances with grounded fundamentals.
- Chase early strength in income-focused opportunities using the 160 dividend fortresses, built to flag high-yield payers where payouts and balance sheets both sit in focus.
- Track where real profits meet AI buzz through the 38 profitable AI stocks that aren't just burning cash so you focus on cash-generating platforms rather than stories that rely on hope.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com